Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2010
May 2010, Vol 1, No 1
May 2010, Vol 1, No 1
Breast Cancer Survival Improves, Thanks to New Therapies
May 2010, Vol 1, No 1
Barcelona—Survival for patients with metastatic breast cancer has improved dramatically in the last 20 years, especially in the subgroup of patients with HER2-positive tumors, according to research presented at the 7th European Breast Cancer Conference (EBCC7).
Read Article
NCCN Roundtable: Clinical and Economic Issues Impacting Cancer Care Delivery
NCCN Conference
May 2010, Vol 1, No 1
At a roundtable held during the NCCN’s 15th Annual Conference, moderator Clifford Goodman, PhD, Senior Vice President at The Lewin Group, predicted, “The appropriate use of evidence-based guidelines is on a collision course with the financial nonsustainability of the healthcare system.”
Read Article
New Tools Arriving to Measure and Manage Chemotherapy Care
ACCC Conference
May 2010, Vol 1, No 1
Researchers from the University of California and the University of California San Diego (UCSD) have begun working on a prototype “cyberinfrastructure” that would allow cancer researchers to collect and interpret data from multiple sources to compare the effectiveness of preventive measures, drugs, treatments, and interventions during the course of clinical trials.
Read Article
Evolution in Oncology Practice Management: Part 1
Practice Management
,
Value Peer-spectives
May 2010, Vol 1, No 1
As health plans grapple with the rapidly rising cost of oncology medications and a “buy and bill” system that does not work for physicians or for the plans, they are seeking new strategies for providing these life-saving drugs to their members and for freeing up oncology and hematology practices to focus solely on caring for patients, not managing a pharmacy.
Read Article
Oncology-related Updates from the US Food and Drug Administration
FDA Approvals, News & Updates
May 2010, Vol 1, No 1
Read Article
Reimbursement for Expensive Cancer Therapies: The Role of Cost-effectiveness Analysis
By
Gary C. Yee, PharmD, FCCP, BCOP
Economics & Value
,
Health Economics
May 2010, Vol 1, No 1
Due to changes in the US Food and Drug Administration (FDA) approval process for cancer drugs, many new cancer drugs have been approved over the past 10 to 15 years. Although the availability of these new drugs has improved survival for many cancer patients, there is increasing concern over the cost of these agents.
Read Article
New Colorectal Cancer Therapies Foster New Discussions on the Value of Medications
Colorectal Cancer
May 2010, Vol 1, No 1
New chemotherapies for metastatic colon cancer have improved life expectancy, but at a significant cost, say the authors of a study that explores the value of medications including bevacizumab (Avastin, Genentech), capecitabine (Xeloda, Roche Laboratories), cetuximab (Erbitux, Bristol-Myers Squibb), irinotecan hydrochloride (Camptosar, Pfizer, Inc), and oxaliplatin (Eloxatin, Sanofi-Aventis LLC).
Read Article
For Dying Patients, Emergency Care Is Less than Ideal
End-of-Life Care
,
Policies & Guidelines
May 2010, Vol 1, No 1
A Canadian study examining the reasons why a patient with cancer will visit the emergency department near the end of life points out shortcomings in current care delivery systems and suggests a greater role for more effective palliative care, say the authors.
Read Article
Existing Test May Have New Use in Anthracycline Targeting
EBCC7 Conference
May 2010, Vol 1, No 1
Barcelona—A meta-analysis of 4 large breast cancer trials reveals that a particular chromosome abnormality is a highly significant indicator that a patient’s breast cancer will respond to anthracycline therapy, announced an international team of researchers at the EBCC7 meeting.
Read Article
Protein Offers Expanded Predictive Significance in Early Breast Cancer
May 2010, Vol 1, No 1
Barcelona—A protein previously thought to exist only in a limited number of tumors in fact exists across all breast cancer subtypes, a finding that can help predict the tumor’s response to chemotherapy and guide treatment decisions.
Read Article
Page 2 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma